Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety. Latest Ratings for IMUX Date Firm Action From To Sep 2021 HC Wainwright & Co. Maintains Buy Apr 2021 Aegis Capital Initiates Coverage On Buy Mar 2021 JMP Securities Initiates Coverage On Market Outperform View More Analyst Ratings for IMUX View the Latest Analyst Ratings Importance Rank: 1 read more

Go to News Site